Trial reportClimacteric : the journal of the International Menopause Society2015
MsFLASH participants' priorities for alleviating menopausal symptoms.
Trial report in Climacteric : the journal of the International Menopause Society, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Variation in menopausal vasomotor symptoms outcomes in clinical trials: a systematic review.BJOG : an international journal of obstetrics and gynaecology · 2020Pooled it
- Improving vasomotor symptoms; psychological symptoms; and health-related quality of life in peri- or post-menopausal women through yoga: An umbrella systematic review and meta-analysis.Complementary therapies in medicine · 2017Pooled it
- Oral micronized progesterone for perimenopausal night sweats and hot flushes a Phase III Canada-wide randomized placebo-controlled 4 month trial.Scientific reports · 2023Trial
- Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes: a phase 2, randomised, double-blind, placebo-controlled trial.Lancet (London, England) · 2017Trial
- Risk factors, management and consequences of severe menopausal vasomotor symptoms.Nature reviews. Endocrinology · 2026Review
- Exercise Habits, Preferences, Barriers, and Facilitators in Midlife Women.Exercise, sport & movement · 2026Article
- Estradiol and Micronized Progesterone: A Narrative Review About Their Use as Hormone Replacement Therapy.Journal of clinical medicine · 2025Review
- Article
- Seeking Health Care for Perimenopausal Symptoms: Observations from The Women Living Better Survey.Journal of women's health (2002) · 2023Article
- Protocol for development of a core outcome set for menopausal symptoms (COMMA).Menopause (New York, N.Y.) · 2020Article
- Lights on MsFLASH: a review of contributions.Menopause (New York, N.Y.) · 2020Review
- Neurokinin 3 Receptor Antagonists Do Not Increase FSH or Estradiol Secretion in Menopausal Women.Journal of the Endocrine Society · 2020Article
- Consequences of premature ovarian insufficiency on women's sexual health.Przeglad menopauzalny = Menopause review · 2018Review
- Neurokinin 3 receptor antagonism rapidly improves vasomotor symptoms with sustained duration of action.Menopause (New York, N.Y.) · 2018Article
- Treating hot flushes with a neurokinin 3 receptor antagonist.Oncotarget · 2017Article
- Factors associated with sexual quality of life among midlife women in Serbia.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2017Article
- Validity, cut-points, and minimally important differences for two hot flash-related daily interference scales.Menopause (New York, N.Y.) · 2017Article
- Female Sexual Function Index Short Version: A MsFLASH Item Response Analysis.Archives of sexual behavior · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
objectiveTo describe self-reported menopausal symptom priorities and their association with demographics and other symptoms among participants in an intervention trial for vasomotor symptoms (VMS).
methodsCross-sectional study embedded in the MsFLASH 02 trial, a three-by-two factorial design of yoga vs. exercise vs. usual activity and omega-3-fatty acid vs. placebo. At baseline, women (n = 354) completed hot flush diaries, a card sort task to prioritize symptoms they would most like to alleviate, and standardized questionnaires.
resultsThe most common symptom priorities were: VMS (n = 322), sleep (n = 191), concentration (n = 140), and fatigue (n = 116). In multivariate models, women who chose VMS as their top priority symptom (n = 210) reported significantly greater VMS severity (p = 0.004) and never smoking (p = 0.012), and women who chose sleep as their top priority symptom (n = 100) were more educated (p ≤ 0.001) and had worse sleep quality (p < 0.001). ROC curves identified sleep scale scores that were highly predictive of ranking sleep as a top priority symptom.
conclusionsAmong women entering an intervention trial for VMS and with relatively low prevalence of depression and anxiety, VMS was the priority symptom for treatment. A card sort may be a valid tool for quickly assessing symptom priorities in clinical practice and research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.